日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A highly potent, stable, and safe dePEGylated lipopeptide against Nipah virus and related henipaviruses

一种高效、稳定且安全的去聚乙二醇化脂肽，可对抗尼帕病毒及相关亨尼帕病毒

期刊:Emerging Microbes & Infections
影响因子:7.5
doi:10.1080/22221751.2025.2610858
Wang, Yuanzhou; Wang, Cong; Zhou, Jie; Zhang, Guangxu; Xiu, Ruixue; Wu, Shuang; Xu, Wei; Hu, Mengyu; Xia, Shuai; Shi, Yuren; Lin, Siyu; Yin, Yuan; Lu, Lu; Zhu, Yun; Jiang, Shibo; Wang, Qian
微生物学
发表日期：2026
文献求助 收藏

A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus.

基于 VLP 的 mRNA 疫苗可诱导针对奥罗普切病毒的强效体液免疫和细胞免疫。

期刊:mBio
影响因子:4.7
doi:10.1128/mbio.03653-25
Shi Yuren, Zhang Guangxu, Lin Siyu, Hu Mengyu, Wang Yuanzhou, Ge Haoyu, Xia Shuai, Wang Qian, Jiang Shibo, Lu Lu
细胞生物学
发表日期：2026
文献求助 收藏

Advances in human respiratory organoid models for studying the pathogenesis and intervention strategies of COVID-19

利用人类呼吸系统类器官模型研究COVID-19的发病机制和干预策略的进展

期刊:Virologica Sinica
影响因子:4
doi:10.1016/j.virs.2026.02.002
Shan, Zeping; Li, Jiarui; Ye, Zihui; Chen, Yuyue; Chen, Jie; Chen, Yuewen; Wang, Xiaofan; Gao, Chong; Jiang, Shibo; Zhang, Naru
3D/类器官
发表日期：2026
文献求助 收藏

Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors

泛冠状病毒融合抑制剂EK1与RBD特异性抗体或M(pro)抑制剂联合使用，具有强大的体外协同抗病毒作用

期刊:Journal of Virology
影响因子:3.8
doi:10.1128/jvi.00076-26
Xiu, Ruixue; Wang, Yuanzhou; Cai, Wenbo; Wang, Qian; Xie, Minxiang; Wang, Yingdan; Li, Cheng; Wang, Qiao; Huang, Jinghe; Ying, Tianlei; Song, Chuanjun; Lu, Lu; Jiang, Shibo; Xu, Wei
微生物学
发表日期：2026
文献求助 收藏

Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies

2025 年基孔肯雅热：病毒学、诊断、疫苗和抗病毒疗法的全面见解

期刊:Viruses-Basel
影响因子:3.5
doi:10.3390/v18010100
Zheng, Zeyong; Ji, Hua; Shan, Zeping; Xu, Jiangcheng; Li, Jiarui; Zhang, Xueting; Zheng, Jiajia; Jiang, Shibo; Zhang, Naru
微生物学
发表日期：2026
文献求助 收藏

Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution.

孤儿广谱 RBD 结合抗体对 SARS-CoV-2 进化过程中剩余的三个保守 RBD 表位进行了注释。

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-65596-0
Xie Minxiang, Qiu Yinong, Zhao Xiaoyu, Shi Jialu, Liu Yuanchen, Zhang Qingsong, He Jiaying, Li Jiayan, Liu Luotian, Sun Siyuan, Zhu Yuzhen, Mao Qiyu, Long Yiming, Oliveira Thiago Y, Wang Zijun, Zhou Yunjiao, Yan Yan, Xia Anqi, Zai Wenjing, Mayer Christian T, Xie Youhua, Jiang Shibo, Lu Lu, Xia Rong, Wu Fan, Sun Lei, Wang Pengfei, Chu Hin, Wang Qiao
SARS-CoV-2
发表日期：2025
文献求助 收藏

A5-A dual-target antiviral compound that rewrites the rules of influenza therapy

A5——一种双靶点抗病毒化合物，它改写了流感治疗的规则。

期刊:Acta Pharmaceutica Sinica B
影响因子:14.6
doi:10.1016/j.apsb.2025.07.033
Jiang, Shibo
微生物学
流感
发表日期：2025
文献求助 收藏

Dual-targeting strategy enables extremely potent and broad inhibition of emerging MERS-related coronaviruses

双靶向策略能够对新出现的MERS相关冠状病毒实现极其有效和广泛的抑制。

期刊:Cell Discovery
影响因子:12.5
doi:10.1038/s41421-025-00827-8
Jiao, Fanke; Jin, Suya; Wang, Qian; Xu, Wei; Wang, Xinling; Sun, Fei; Lu, Lu; Jiang, Shibo; Zhu, Yun; Xia, Shuai
微生物学
发表日期：2025
文献求助 收藏

Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants.

利用疫苗接种减轻原始抗原罪，以增强针对 SARS-CoV-2 Omicron 亚型的广谱中和抗体反应

期刊:MedComm
影响因子:10.7
doi:10.1002/mco2.70273
Zhang Guangxu, Wang Qian, Ji Kai, Wang Yuanzhou, Xu Wei, Zhou Jie, Liu Zezhong, Xiu Ruixue, Xing Lixiao, Zhou Jianghao, Shi Yuren, Lu Xishan, Wang Xuanyi, Ying Bo, Lu Lu, Jiang Shibo
炎症/感染
新冠
发表日期：2025
文献求助 收藏

Predicted early fusion intermediates in the spike of ACE2-utilising bat coronavirus unveil broad-spectrum antiviral mechanisms

预测的蝙蝠冠状病毒刺突蛋白中早期融合中间体（利用ACE2）揭示了广谱抗病毒机制

期刊:Clinical and Translational Medicine
影响因子:6.8
doi:10.1002/ctm2.70459
Sun, Lujia; Liu, Zhimin; Xing, Lixiao; Liang, Xiaoxing; Lu, Lu; Jiang, Shibo; Sun, Lei; Wang, Xinling
微生物学
ACE2
发表日期：2025
文献求助 收藏